Clinical Trials · NCT00615836
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 554
- Start date
- Dec 2007
- Locations
- 73 sites, United States, Canada
- Primary endpoint
- Change From Baseline in Mean Number of Nocturnal Voids